Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

252 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer.
Leboulleux S, Schroeder PR, Busaidy NL, Auperin A, Corone C, Jacene HA, Ewertz ME, Bournaud C, Wahl RL, Sherman SI, Ladenson PW, Schlumberger M. Leboulleux S, et al. J Clin Endocrinol Metab. 2009 Apr;94(4):1310-6. doi: 10.1210/jc.2008-1747. Epub 2009 Jan 21. J Clin Endocrinol Metab. 2009. PMID: 19158200
Diagnostic accuracy of 18F-FDG PET/CT for assessing response to radiofrequency ablation treatment in lung metastases: a multicentre prospective study.
Bonichon F, Palussière J, Godbert Y, Pulido M, Descat E, Devillers A, Meunier C, Leboulleux S, de Baère T, Galy-Lacour C, Lagoarde-Segot L, Cazeau AL. Bonichon F, et al. Among authors: leboulleux s. Eur J Nucl Med Mol Imaging. 2013 Dec;40(12):1817-27. doi: 10.1007/s00259-013-2521-9. Epub 2013 Sep 17. Eur J Nucl Med Mol Imaging. 2013. PMID: 24042540 Clinical Trial.
Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors.
Seban RD, Mezquita L, Berenbaum A, Dercle L, Botticella A, Le Pechoux C, Caramella C, Deutsch E, Grimaldi S, Adam J, Ammari S, Planchard D, Leboulleux S, Besse B. Seban RD, et al. Among authors: leboulleux s. Eur J Nucl Med Mol Imaging. 2020 May;47(5):1147-1157. doi: 10.1007/s00259-019-04615-x. Epub 2019 Nov 21. Eur J Nucl Med Mol Imaging. 2020. PMID: 31754795
The intensity of 18FDG uptake does not predict tumor growth in patients with metastatic differentiated thyroid cancer.
Terroir M, Borget I, Bidault F, Ricard M, Deschamps F, Hartl D, Tselikas L, Dercle L, Lumbroso J, Baudin E, Berdelou A, Deandreis D, Schlumberger M, Leboulleux S. Terroir M, et al. Among authors: leboulleux s. Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):638-646. doi: 10.1007/s00259-016-3551-x. Epub 2016 Oct 29. Eur J Nucl Med Mol Imaging. 2017. PMID: 27796544
¹⁸Fluorocholine PET/CT in parathyroid carcinoma: a new tool for disease staging?
Deandreis D, Terroir M, Al Ghuzlan A, Berdelou A, Lacroix L, Bidault F, Troalen F, Hartl D, Lumbroso J, Baudin E, Schlumberger M, Leboulleux S. Deandreis D, et al. Among authors: leboulleux s. Eur J Nucl Med Mol Imaging. 2015 Nov;42(12):1941-2. doi: 10.1007/s00259-015-3130-6. Epub 2015 Aug 9. Eur J Nucl Med Mol Imaging. 2015. PMID: 26253272 No abstract available.
Screening in asymptomatic SDHx mutation carriers: added value of ¹⁸F-FDG PET/CT at initial diagnosis and 1-year follow-up.
Lepoutre-Lussey C, Caramella C, Bidault F, Déandreis D, Berdelou A, Al Ghuzlan A, Hartl D, Borget I, Gimenez-Roqueplo AP, Dumont F, Deschamps F, Nascimento C, Lumbroso J, Guillaud Bataille M, Schlumberger M, Baudin E, Leboulleux S. Lepoutre-Lussey C, et al. Among authors: leboulleux s. Eur J Nucl Med Mol Imaging. 2015 May;42(6):868-76. doi: 10.1007/s00259-015-3003-z. Epub 2015 Feb 13. Eur J Nucl Med Mol Imaging. 2015. PMID: 25676472
252 results